SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
FBIO

Fortress Biotech, Inc. (NASDAQ:FBIO)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$1.90+$0.13 (+7.34%)
 
Market cap
$63.6M
Insider Score
Health Score
Analyst consensus
Listed since
Nov 17, 2011
Market Cap$63.63M-25.5%
Revenue (ttm)$69.99M+12.3%
Net Income$100.12M+2411.2%
EPS$2.34+907.6%
Shares Out33.49M
PE Ratio0.65
Forward PE2.77
Dividendn/a
Ex-Dividend Daten/a
Volume739,058
Open$1.86
Previous Close$1.77
Day's Range$1.84 - $1.99
52-Week Range$1.64 - $4.53
Beta1.25
AnalystsBuy
Price Target$5.00(+163.16%)
Earnings DateMar 30, 2027

About FBIO

Fortress Biotech, Inc. operates as a biopharmaceutical firm dedicated to the development and commercialization of a diverse range of pharmaceutical and biotechnology products. The company currently offers a portfolio of dermatological treatments. These include Ximino and Targadox, both formulated to address various forms of acne (ranging from moderate-to-severe inflammatory lesions to severe cases). Other products in this segment are Exelderm cream for fungal skin infections like ringworm and jock itch, Ceracade for dry skin conditions, Luxamend for wound care, and Accutane capsules for particularly severe, stubborn nodular acne. Its pipeline features several promising late-stage drug candidates, targeting a diverse range of medical needs. These include intravenous Tramadol for acute post-operative pain, CUTX-101 (an injection for Menkes disease), MB-107 and MB-207 for X-linked severe combined immunodeficiency, Cosibelimab for metastatic cancers, CK-101 for non-small cell lung cancer characterized by EGFR mutations, CAEL-101 for amyloid light chain (AL) amyloidosis, the Triplex vaccine for cytomegalovirus, and CEVA101 for critical traumatic brain injuries in adults and children. Furthermore, its earlier-stage research encompasses various investigational treatments such as MB-102 for blastic plasmacytoid dendritic cell neoplasm, MB-101 for glioblastoma, MB-104 for multiple myeloma and light chain amyloidosis, MB-106 for B-cell non-Hodgkin lymphoma, MB-103 for glioblastoma and metastatic breast cancer to the brain, MB-108, MB-105 for prostate and pancreatic malignancies, and BAER-101. In the preclinical phase, Fortress Biotech is exploring an array of novel therapeutic approaches. These comprise AAV-ATP7A and AVTS-001 (both gene-based therapies), the CK-103 BET inhibitor, CEVA-D and CEVA-102, CK-302 (an antibody targeting GITR), CK-303 (an antibody against CAIX), ConVax, and the ONCOlogues oligonucleotide platform. The company also actively engages in collaborative ventures with universities, research institutions, and other pharmaceutical organizations. Originally established in 2006, the entity operated as Coronado Biosciences, Inc. before rebranding as Fortress Biotech, Inc. in April 2015. Its corporate headquarters are situated in Bay Harbor Island, New York.

Address
1111 Kane Concourse, Bay Harbor Islands, FL, 33154, US
Market Cap
64 million
Employees
78
Industrial Classification
Biotechnology

Fortress Biotech, Inc. Stock Analysis — InsiderScore

Insider Score
See top-rated InsiderScore stocks ›
46th Percentile Overall Score
FBIO InsiderScore:66 / 99

Fortress Biotech, Inc. scored higher than 46% of companies evaluated by InsiderBuying, and ranked 43rd out of 110 stocks in the biotech sector.

Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.

Dollars Committed

Insiders at Fortress Biotech, Inc. bought $340.4K of stock across 6 purchases in the last 90 days, the largest of them $115.9K.

Stake Increase

The average purchase added about 1% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.

New Positions

Every buyer already held stock, so each purchase is an increase rather than a first position.

This category carries 35% of the Insider Score.

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$340.40K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Strong
From FBIO’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
+7.34%
5 Days
+3.26%
1 Month
-4.52%
6 Months
-30.66%
1 Year
-25.49%

$FBIO stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in FBIO holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by FBIO's directors and management

Net Shares Purchased by Insiders−200k−100k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

FBIO Estimated quarterly lobbying spending

Source: U.S. Senate LDA

FBIO Revenue by Segment

$19.16MTotal
Emrosi$9.00M46.99%
Qbrexza$5.59M29.18%
Accutane$3.02M15.78%
Foam franchise products (Amzeeq & Zilxi)$942.00K4.92%
Other / legacy product revenue$263.00K1.37%
Other revenue$234.00K1.22%
Eurax$105.00K0.55%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New FBIO patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to FBIO from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in FBIO

VTIVanguard Morningstar Total Stock Market ETF$1.06M
VXFVanguard Extended Market ETF$597.30K
IWCiShares Micro-Cap ETF$141.64K
BSVOEA Bridgeway Omni Small-Cap Value ETF$50.00K
AVSCAvantis U.S. Small Cap Equity ETF$5.26K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from FBIO’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
56.34
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
62

News check: Q3 2026 earnings released with reported results, insider buying, and new FB-607 license deal for IBS-D treatment signals operational progress and management confidence.

Recent Insider Activity

Buys
6
Sells
0
Buy Value
$340.40K
Distinct Buyers
2

Insider Score Trend Over Time

-0.2 since Nov 20
0255075100Nov 20 — Insider Score 66.0Nov 21 — Insider Score 65.7Nov 22 — Insider Score 65.9Nov 20Nov 21Nov 22

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

BSVOEA Bridgeway Omni Small-Cap Value ETF0.00%

Weight is the stock’s share of each fund’s holdings.